Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

about

MRI Characterizes the Progressive Course of AD and Predicts Conversion to Alzheimer's Dementia 24 Months Before Probable Diagnosis.

P2860

Q55462397-5CFFABCE-EF20-4DCB-9B24-C37267DB33DB

P2860

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

Item

http://www.wikidata.org/entity/Q39296351

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@en

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@nl

type

Item

label

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@en

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@nl

prefLabel

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@en

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

@nl

P1476

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets

@en

P2093

Ayesha Khan

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial

Putting brain training to the test.

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

Exercise training increases size of hippocampus and improves memory

A molecular link between the active component of marijuana and Alzheimer's disease pathology

5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

P304

683-695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737175.2017.1326818

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Clive Ballard

Anne Corbett

P577

2017-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28490260

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

about

P2860

P2860

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921